Recruiting PHASE2 INTERVENTIONAL 1-arm
NCT06849167
Immunotherapy Combined with Hypofractionated Concurrent Chemoradiotherapy Followed by Immunotherapy in LA-NSCLC
A Single-Arm Phase II Clinical Trial of Immunotherapy Combined with Hypofractionated Concurrent Chemoradiotherapy Followed by Immunotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer
Sponsor: Peking University Cancer Hospital & Institute
Conditions
Non-Small Cell Lung Cancer
Interventions
hypofractionated radiotherapy with immunotherapy
Updated 1 time since 2025 Last updated: Feb 24, 2025 Started: Mar 1, 2025 Primary completion: Mar 1, 2029 Completion: Mar 1, 2030
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT06849167, this PHASE2 trial focuses on Non-Small Cell Lung Cancer and remains actively recruiting participants. Sponsored by Peking University Cancer Hospital & Institute, it has been updated 1 time since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
1 version recorded Recruiting — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Peking University Cancer Hospital & Institute
Data source: Peking University Cancer Hospital & Institute
For direct contact, visit the study record on ClinicalTrials.gov .